

# **Sodality Summary**

# Sodality Profiles

Name of Sodality:	CSIA (Clinical Service In ASIA)		
Establishment:	2015		
Member Company:	[CSIA-SMO][CSIA-CRO]• Medical System Research Corp. (Japan)• SRD Co., Ltd. (Japan)• SitePartner Corporation (Taiwan)• GCP ClinPlus Co., Ltd. (China)• SMO ClinPlus Co., Ltd. (China)• MedPlus1 Co., Ltd. (Vietnam)• MedPlus1 Co., Ltd. (Vietnam)• MedPlus1 Co., Ltd. (Vietnam)		
Contact Information:	RBM Kyobas	. & Medical System Research Corp. hi Bldg, 3-4-8 Hatchobori, Chuo-ku, Tokyo 104-0032 Japan 543-0521 FAX: +81-3-5543-0184 Email: global@cro-srd.co.jp	
	200001 TEL: +86 189 GCP ClinPlus F16, Building	333 Finance Square, Jiujiang Road, Huangpu District, Shanghai, China 911101063 Email: bd@smo-clinplus.com	
		orporation 8, Songjiang Rd, Zhongshan Dist., Taipei City 104, Taiwan 2593-1818 FAX: +886-2-2587-3589	
	City, Vietnam	Bldg. 74C-G Nguyen Van Cu Str. Nguyen Cu, Trinh Ward, Dist. 1, HCM	
	1515 south TEL: +1 76 - Business De BDa25 You Tel: +1 78	gement and Statistics Operation melrose drive, vista, CA 92081 0 405 5703 evelopment ng Avenue Swampscott, Boston, MA 01907 USA	
	EU GCP ClinPlus Bishops Squa Tel: +44 777	s Co., Ltd. re Business Park Al10 9NA Hatfield, Hertford shire UK	
Service Description:	Contracted clinical research development services for pharmaceuticals, medical devices, quasi-drugs, in-vitro diagnostics, healthy foods, and cosmetics in health care industry		



## Founder



### Hiromi Tazawa President & CEO, SRD Co., Ltd.

CSIA supports with abounding experiences and utilizing original method centering the customer request and mutual trust.

Healthcare Market in Asia is rapidly expanding more than we expected by supporting of economical rapid growth in Asia. For tracking this rapid growth, CSIA is established to provide the One Stop Solution of Clinical Development Service to our customers by gathering the knowledge and knowhow of deeply rooted SMOs and CROs in each Asia region.

For corresponding with the change of clinical development trend, CSIA provides the services with adequate accuracy and quality using with flexibility and broadranging information networks to fulfill our customer needs in any therapeutic areas. It is our great pleasure that you would expect our outstanding future activities



**Co-founders** 

### Charlie Chen

Chief Executive Officer, GCP ClinPlus Co., Ltd.

CSIA provides truly integrated one-stop solution for our clients across Asia Pacific region, from site resources, protocol design, to Regulatory support.



## Fiona Yu

Chief Executive Officer, SitePartner Corporation

By performing clinical trial in Asia, CSIA not only is more cost effective, but creates a high level of efficiency as well.



### David Yang

Chief Executive Officer, SMO ClinPlus Co., Ltd.

The best solution for conducting a clinical study is "to do it in right way" rather than "to monitor". SMO is an effective solution for most clinical studies in Asia. With our assistant, you will be able to accelerate the timeline and ensure the quality of studies.



### Takeshi Abe

Chief Executive Officer, Medical System Research Corp.

As a pathfinder of SMO in Japan, we gradually expanding our capability in various therapeutic areas for providing adequate support to our customers Complying with ICH-GCP and ALCOA, etc. and are making effort to become close partner with our customers. With our conscientious support, you will receive higher quality service level with that of a competent SMOs.



### Shinichi Tamura

President, MedPlus1 Co., Ltd.

Providing and performing high quality SMO/CRO services in accordance with ICH-GCP and local regulations in Vietnam. Especially in SMO services, CSIA will provide high quality services even you would request with high level requirements for your successful achievement.



# **CSIA-CRO** Member History

2016

	5-0	Contraction of the second seco				
1989	• SRD Co., Ltd. was established with the capital of around	0.16 mil. USD				
1992	Capital increased to 0.24 mil. USD					
1997	Capital increased to 0.32 mil. USD					
1999	Separated SMO service department as MSR	GCP ClinPlus				
2003	SRD Biology Center (Non-clinical Lab Service) was     established	Beijing DMS Pharma Ltd was established				
2004	IR Juhan (Real Estate) was established	YiXie ZhongTai MedTech Consulting Ltd (Medical Device) was established				
2005	SRD Biology Center, Shibukawa Laboratory was     opened in Gummna					
2008	• _20 <sup>th</sup> Anniversary	Over 300 clinical trials successfully completed				
2009	Capital increased to 0.4 mil. USD	SMO business officially started				
2010	International clinical trial support service started	GCP ClinPlus was established by merging three companies				
2012	<ul> <li>SRD Staff (dispatch business) was established</li> <li>Acquired 1st class medical device marketing authorization holder</li> <li>International clinical trial support service is</li> </ul>	GCP USA was established				
2013	officially established as Dept. of Global Project Management 25 <sup>th</sup> Anniversary	SMO ClinPlus separated as independent subsidiary of GCP ClinPlus with the capital of 0.16 mil. USD				
2014		GCP US Operation Team started  MedPlus1 Co., Ltd.				
2015	<ul> <li>Hired &gt;200 employees</li> <li>SRD elaborated CSIA plan for Asia clinical development</li> </ul>	<ul> <li>GCP EU was established</li> <li>Hired &gt;200 employees</li> <li>Covers 50 cities in China until 2015</li> <li>SRD established as a first authorized SMO in Vietnam with Shinichi Tamura (CEO) and the capital of 0.24 mil. USD</li> <li>Hired &gt;10 employees</li> </ul>				
2016	client: • System	(Clinical Service In Asia) is established and all 3 companies above joined as member to support s for accurate, smooth, and reliable clinical trial conductions m developed for supporting small to large population of clinical trial in Asia rs main cities in Asia for potential clinical trial conductions				



## **Service Center**

# THINK GLOBALLY ACT LOCALLY

Customer-oriented Service Engagement

CSIA-CRO will provide clinical development solutions for matching customer needs based on the customer request by constructing professional team from the US, Japan, China, Taiwan, Korea, and/or Vietnam. Professional team member will perform high quality service with effective operation for development support duties to achieve customer goals

Service Portfolio

Usually, Asian study or study including Asian countries were mainly supported or consulted by big global CROs. However, CSIA-CRO provides the service with high level know-how and high speed performance based on the experienced and cultivated information rooted by each local CROs

S Asia Network Service Model

CSIA-CRO will provide best clinical development strategies as a solution to satisfy customer needs by collaborating with CSIA-SMO which has a network of strong partnership with local institutions. This model will be the first initiated service in the world, and will provide a high quality performance corresponding to the cultural background and legal requirements by local rooted CROs and SMOs



\* CSIA will collect the information from several CROs in Korea and Taiwan for selecting service provider by the customer to satisfy the needs, and will operate clinical trial conducted in these countries.

# **Market Value**



#### CSIA-CRO

is the pioneer of first Asia CRO group by integrating the clinical development with the Site Management Organization Group in ASIA

Full Support Solution

CSIA will perform a full clinical development support service with CSIA information exchange system which the customers have never experienced by using the effective mobility and flexibility of CRO and SMO which they closely and directly feel the rapid changing condition and environment of clinical development in Asia

Quality Management

CSIA will share all the issues such as protocol violations and adverse events occurred within participated countries and regions on the project level to increase the entire study quality. And the policy of the CSIA is to provide maximum benefit to our customer corresponding by risk-based and remote monitoring, and complying with ALCOA, ICH-GCP, and local laws and regulations

#### Information Sharing System


Using the certain system also used as training system, CSIA will provide any customer's product related information to the customer to achieve that the customer has never experienced such a high quality fast clinical development service



# **Experienced Therapeutic Areas**

Wide Variety of Disease Experiences and Asia Specialized Strategy

In General, mid sized CROs have a major issue to cover wide range of disease experiences by crossing the boarder, and to maintain and train the specialty as a CRO. CSIA-CRO, however, share the cultivated specialty within the 3 companies including IND submission to US-FDA to fulfill the customer satisfaction, also with additional information regarding the actual Asian clinical condition and environment from CSIA-SMO. Over 1000 studies including the experiences from CSIA-SMO leads to set up the training system which is specialized in the subjective disease of our customer for providing the best performance with reliability. As a rooted CRO in each regions, CSIA-CRO will provide precious information to the customer by strong and good relationship with investigational institutions with cooperation of CSIA-SMO



#### Number of Studies in Each Disease Category

#### Training System

CSIA-CRO will construct web-based training system specialized in the customer's developing product before its clinical study start (after finalization of the study protocol). The well-experienced and specialists in the CSIA-CRO will share the expected issues through the system and all the CRAs and CRCs who will involve the study will be able to access these system to be trained before the subject recruitment. After the study starts, the system is also able to use as a communication platform so that the customer also will access to supervise the study and to solve any issues timely for smooth and effective operation.

#### Social Intercourse

CISA-CRO has a ordinarily 20 or more managers and leader who are experienced with various disease area, and most appropriate manager and leader will comprehensively control the study.

They are constructing close relationship for smooth and effective operation for the customer by having several social intercourse within three companies each year to provide the customer for easy control of entire cross boarder project





## **Service Description**

#### Service of CSIA-CRO

CSIA-CRO provides a full support CRO service with reasonable price and tender care as equal service compared to the big global CRO to launch the customer's developing product even a little early from the beginning through the end including regulatory related tasks, medical writing, monitoring, and preparation of Common Technical Document.

	Pharmaceutical Drugs			Medical Devices	
-		Regulatory authority (RA) consulting Feasibility research Site selection Monitoring Quality control Subject registration and randomization Drug management		Site selection Monitoring	
		Data Management Bio-statistics Medical writing Safety Management GCP audit Correspondence of document-based audit NDA Consulting NDA preparation support In-country clinical care taker bjectives ] Phase I – IV clinical trials		Quality control Subject registration an Device management Data Management Bio-statistics Medical writing Safety Management GCP audit Correspondence of doo Consultation of applic Application document	
		Clinical studies / researches Investigator initiated studies PMS	•	support In-country clinical car	

#### Generic Drugs

- Development consulting
- □ Site selection
- Monitoring
- Quality control
- **u** Subject registration and randomization
- Drug management
- Data Management
- Bio-statistics
- Medical writing
- GCP audit
- Correspondence of on-site audit
- Consultation of application for approval
- Application documents preparation support
- In-country clinical care taker

- nsulting ing essary test nd randomization ocument-based audit cation for approval its preparation re taker
  - Others (Quasi-drugs, Cosmetics, IVD, Health Food)
  - Site selection
  - Monitoring
  - Quality control
  - Subject registration and randomization
  - Drug management
  - Data Management
  - **Bio-statistics**
  - Medical writing
  - GCP audit
  - Correspondence of on-site audit
  - Consultation of application for approval



Bio-statistics and data management team is capable with SAS, IWRS, CDISC compliant EDC (EclinicalOS, Inform, Viedoc), and MedDRA, and provide the service along with the customer needs. Also CSIA provides CTMS service upon the customer request to satisfy the needs of entire project management





## **Description of Service Proposal**

#### Proposal of Clinical Trial Plan and Quotation

CSIA-CRO will propose a clinical trial plan including all the information of member countries and regions based on the customers requests, and also more precious information with the cooperation from CISA-SMO. If the customer needs a consultation or has a intention to offer the project prior to the contract, CSIA-CRO will provide additional information to the customer .


#### Proposal Example of CSIA-CRO

- Member company profiles
- Experienced disease area and achievements
- □ Trends and general regulation information
- General condition of requested disease in each countries
- Management plan
- Resource plan
- Recruitment plan
- Cost reduction scheme
- Risk management plan
- Consulting Service
  - RA consulting for requested project
    - Comprehensive milestone/ timeline set up until CTD submission

Mutual Cooperation

Example of Integrated Proposal of CSIA-CRO and CSIA-SMO

- Member company profiles
- Experienced disease area and achievements
- **Trends and general regulation information**
- General condition of requested disease in each countries
- KOL candidate list
- **Candidate principle investigator and investigational sites**
- Experiences of investigators
- Patients population of each sites
- □ Management plan
- Resource plan
- Recruitment plan
- Cost reduction scheme
- Risk management plan
- Consulting Service
  - RA consulting for requested project
    - Comprehensive milestone/ timeline set up until CTD submission



\*Feasibility research and China medical device registration orders will be consulted separately.



It will require large amount of service fee and resource to determine the potential of customer products in this rapidly changing development environment. CSIA will support the customer with reasonable price for providing strategy set up along with the situation of each countries and regions. CSIA will support you with every effort considering the future of customer developing product using CSIA information sharing system





# **Service Initiation Flow & Description**

